
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma Inc. possesses a promising pipeline of cell therapy products, including LYL797, LYL119, and LYL845, which leverage advanced ex vivo genetic and epigenetic T-cell reprogramming technologies aimed at treating solid tumors. The potential to expand the CAR-T market, particularly in non-Hodgkin lymphoma (NHL) and beyond, supports a favorable commercial outlook, especially if upcoming LYL119 data exceeds expectations. Additionally, the application of a 9% discount rate and a 2% terminal growth rate reflects confidence in the validated therapeutic potential of CD19-targeted approaches, positioning Lyell favorably within the crowded CAR-T landscape.
Bears say
Lyell Immunopharma reported a significant net loss of $0.69 per share for 4Q24, with projections indicating a worsening net loss of $0.73 for the full year 2025, highlighting the company's ongoing struggles in achieving profitability. The company also experienced a decline in the complete response (CR) rate for its product candidates, with a current 63% CR rate compared to a previously reported 77%, raising concerns about the efficacy of its trials. Additionally, despite slightly aligning R&D and SG&A expenses with projections, the company's overall financial outlook remains challenging due to high development risks associated with competing against established standard of care treatments in the cell therapy market.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares